Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
SOPHiA GENETICS SA is a Swiss-based precision medicine company that develops and commercializes cloud-based software for genomic and multimodal data analysis. The company operates at the intersection of healthcare, biotechnology, and artificial intelligence, providing clinical decision-support tools used primarily in oncology and rare disease diagnostics. Its core offering is a software-as-a-service platform that enables hospitals, laboratories, and biopharma companies to analyze complex molecular data and derive clinically actionable insights.
The company’s primary revenue is generated through recurring subscriptions and usage-based fees tied to genomic analyses performed on its platform. SOPHiA GENETICS differentiates itself through a vendor-agnostic approach to sequencing technologies, a globally federated data network, and proprietary AI-driven analytics trained on large-scale, real-world clinical datasets. The company was founded in 2011 and grew from an academic research initiative into a commercial enterprise, culminating in its public listing on the NASDAQ in 2022 under the ticker SOPH.
Business Operations
SOPHiA GENETICS conducts its business through a single integrated operating model centered on its proprietary SOPHiA AI Platform, which supports multiple clinical applications across cancer and inherited disease testing. Key solution areas include solid tumor profiling, hematologic malignancies, homologous recombination deficiency (HRD) assessment, and rare and inherited disorder analysis. The company generates revenue by charging healthcare providers and life sciences partners per analysis and through longer-term subscription agreements.
Operations are global and primarily digital, with software development, data science, and platform maintenance conducted internally. The company controls its core algorithms, cloud infrastructure integrations, and curated datasets, while remaining compatible with a wide range of sequencing instruments. SOPHiA GENETICS operates through subsidiaries including SOPHiA GENETICS Inc., which supports commercial and customer-facing activities, particularly in the United States.
Strategic Position & Investments
The company’s strategy focuses on expanding clinical adoption of its platform, increasing test volumes per customer, and extending its technology into new disease areas and multimodal data types. Growth initiatives include deeper penetration of hospital networks, expansion of biopharma partnerships for translational research and clinical trials, and continued enhancement of AI models through federated data learning.
SOPHiA GENETICS has invested heavily in platform scalability and regulatory-ready solutions rather than pursuing large-scale acquisitions. Its strategic emphasis is on organic growth, selective technology development, and long-term collaborations with healthcare systems and life sciences companies. The company is also involved in emerging areas such as integrated genomic and clinical data analysis, though specific financial returns from these initiatives remain evolving based on available public disclosures.
Geographic Footprint
SOPHiA GENETICS is headquartered in Switzerland, with its principal executive offices located in Rolle, Vaud. The company maintains a significant presence in Europe and North America, which together account for the majority of its revenue and customer base. Additional operations and customers span Asia-Pacific, Latin America, and the Middle East, reflecting a broad international footprint.
The company’s platform is used by hundreds of hospitals and laboratories across more than 50 countries, supported by regional commercial, technical, and customer success teams. While physical infrastructure is relatively asset-light, its international influence is driven by cloud deployment, regulatory clearances in multiple jurisdictions, and long-term institutional customer relationships.
Leadership & Governance
SOPHiA GENETICS was co-founded by Jurgi Camblong, who has played a central role in shaping the company’s vision around democratizing access to advanced genomic analytics. The leadership team emphasizes data-driven medicine, decentralized learning, and close collaboration with clinical institutions as core elements of its strategic philosophy.
Key executives include:
- Jurgi Camblong – Chief Executive Officer
- Kevin C. Phelan – Chief Financial Officer
Public disclosures confirm these leadership roles; information on additional executive appointments varies across sources, and data on other senior executives is inconclusive based on available public sources.